Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second Generation Travoprost Intracameral Implant in Open-Angle Glaucoma or Ocular Hypertension
NCT07075718Phase 2Recruiting
- Sponsor
- Glaukos Corporation
- Start
- Jun 2025
- Primary completion
- Mar 2028
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
A Phase 2 trial of travoprost in Open-angle glaucoma (OAG), ocular hypertension, sponsored by Glaukos Corporation. Started Jun 2025; status: recruiting.
02
Drugs
travoprost
03
Conditions
Open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT07075718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07075718.